Scarica l'app Stockscreener
6.61
5.57%
-0.39
Precedente Chiudi:
$7.00
Aprire:
$5.86
Volume 24 ore:
134.37K
Relative Volume:
3.08
Capitalizzazione di mercato:
$611.37M
Reddito:
$5.12M
Utile/perdita netta:
$-67.00M
Rapporto P/E:
-4.4966
EPS:
-1.47
Flusso di cassa netto:
$-38.94M
1 W Prestazione:
-19.02%
1M Prestazione:
+10.17%
6M Prestazione:
-8.55%
1 anno Prestazione:
-90.88%
Intervallo 1D:
$5.86
$6.78
Intervallo di 1 settimana:
$5.86
$8.16
Portata 52W:
$3.816
$73.40
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Nome
Verrica Pharmaceuticals Inc
Settore
Industria
Telefono
484-453-3300
Indirizzo
10 NORTH HIGH STREET, WEST CHESTER, PA
Confronta VRCA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
6.61 | 64.74M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2023-03-22 | Iniziato | Jefferies | Buy |
| 2023-02-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-24 | Iniziato | Northland Capital | Outperform |
| 2020-03-24 | Iniziato | Needham | Buy |
| 2019-02-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
What analysts say about Verrica Pharmaceuticals Inc. stockExceptional return forecasts - PrintWeekIndia
What drives Verrica Pharmaceuticals Inc. stock priceFree Stock Selection - PrintWeekIndia
Is Verrica Pharmaceuticals Inc. stock overhyped or has real potentialFree Consultation - Newser
VRCA Trading Halted: Anticipation Builds for Pending Announcemen - GuruFocus
Is Verrica Pharmaceuticals Inc. stock a good hedge against inflationRemarkably fast returns - jammulinksnews.com
Verrica Pharmaceuticals Inc. Stock Analysis and ForecastExceptional profit velocity - Autocar Professional
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Announces Reverse Stock Split - TipRanks
Verrica Pharmaceuticals to implement 1-for-10 reverse stock split - Investing.com
Is Verrica Pharmaceuticals Inc. a good long term investmentAccelerated earnings growth - jammulinksnews.com
Published on: 2025-07-19 07:38:47 - jammulinksnews.com
What institutions are buying Verrica Pharmaceuticals Inc. stock nowDaily Trade Opportunity - Newser
What makes Verrica Pharmaceuticals Inc. stock price move sharplyInsider Strategy Insight - Newser
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - newser.com
How Verrica Pharmaceuticals Inc. stock performs during market volatilityFree Stock Trading Community - Newser
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives $8.00 Average Target Price from Brokerages - Defense World
Verrica Reports Strong Q2 Growth as YCANTH Demand Accelerates - MyChesCo
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Down 4.9% – Should You Sell? - Defense World
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 | VRCA Stock News - GuruFocus
Verrica Pharmaceuticals reports 32.8% quarterly growth in YCANTH sales - Investing.com
Verrica Pharmaceuticals Advances Global Phase 3 Trial for YCANTH with Amended Torii Agreement - MyChesCo
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Commo - GuruFocus
Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):